![]() Our ability to organize timely and safe delivery of our products or product candidates by third-parties, any problems with the manufacture, quality or performance of our products or product candidates, the rate and degree of market acceptance from the clinical utility of Lutathera and our other products or product candidates. Our ability to procure adequate quantities of necessary supplies and raw materials for Lutathera and other chemical compounds acceptable for use in our manufacturing processes from our suppliers. Such factors include but are not limited to changing market conditions, the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals, EMA, FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused by or associated with our products and product candidates. ![]() These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Forward-looking statements reflect the company’s current expectation regarding future events and various matters, including expected timing of filings with the FDA and EMA, approval dates and expansion of NETSPOT. The words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, will, would, could, should, continue and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts contained in this conference call including statements regarding the company’s strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. Joining us today are Stefano Buono, Chief Executive Officer Heinz Mausli, Chief Financial Officer Victor Paulus, Head of Regulatory Affairs Claude Hariton, Head of Research and Development and Roger Estafanos, North American Head of Market Access and Pricing.īefore we begin, I’ll remind all listeners that this conference call contains forward-looking statements. Thank you for joining us today, and welcome to the Advanced Accelerator Applications’ year-end 2016 earnings conference call. It is now my pleasure to introduce your host, Jordan Silverstein, Director of Investor Relations. As a reminder, this conference is being recorded. A brief question and answer session will follow the formal presentation. At this time, all participants are in a listen-only mode. ![]() Welcome to the Advanced Accelerator Applications Year-End 2016 Earnings Conference Call. Victor Paulus - Head of Regulatory Affairs Jordan Silverstein - Director of Investor Relations Please be advised that CMS prohibits the use of the miscellaneous code A4641 Radiopharmaceutical, diagnostic, not otherwise classified, on PET claims.Advanced Accelerator Applications ( NASDAQ: AAAP) Q4 2016 Earnings Conference Call Ma10:00 AM ET PET radiopharmaceuticals have their own unique HCPCS codes that can be reported on claims.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |